Nebula Research & Development’s Bio-Rad Laboratories Class A BIO Stock Holding History

Nebula Research & Development’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-926	Closed	-$310K	–	911
2024 Q3	$310K	Buy	+926	New	+$294K	0.04%	705
2024 Q1	–	Sell	-820	Closed	-$265K	–	748
2023 Q4	$265K	Sell	820 -790	-49%	-$248K	0.08%	470
2023 Q3	$577K	Buy	+1,610	New	+$621K	0.3%	101
2023 Q2	–	Sell	-671	Closed	-$321K	–	346
2023 Q1	$321K	Buy	+671	New	+$314K	0.57%	19

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Nebula Research & Development's BIO Position: Q4 2024 in Review

Nebula Research & Development sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 926 shares — an estimated $310K sold.

Nebula Research & Development first reported a position in BIO in Q1 2023 and held it in 4 quarters. The position peaked at $577K in Q3 2023. 456 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

Nebula Research & Development reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
Nebula Research & Development sold 926 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $310K.
Nebula Research & Development first reported a position in Bio-Rad Laboratories Class A in Q1 2023 and held it in 4 quarters.
Nebula Research & Development's Bio-Rad Laboratories Class A position peaked at $577K in Q3 2023.
456 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Nebula Research & Development's 13F filing for Q4 2024, filed 14 Feb 2025.